SR3335

SR3335 is a synthetic selective inverse agonist of RORα with Ki value of 220 nM [1][2].
The retinoic acid receptor-related orphan receptor α (RORα) is an orphan receptor that plays an important role in the regulation of metabolism.
SR3335 prevented the expression of endogenous RORα in HepG2. And it may suppress hepatic glucose production in type 2 diabetics. SR3335 was able to repress the expression of G6Pase. In ChIP trial, ML-176 reduced the amount of SRC2 at the G6Pase promoter [3]. In a GAL4-RORR ligand binding domain cotransfection assay, SR3335 inhibited the constitutive activity of RORα and the Ki was calculated as 220 nM [1].
When treat diet-induced obese mice with SR3335 (15 mg/kg), after injected with pyruvate, the plasma glucose levels were significantly lower at each time point compared with vehicle-treated animals. The results indicated SR3335 suppressed hepatic gluconeogenesis [1].
References:
[1]. Naresh Kumar, Douglas J. Kojetin, et al. Identification of SR3335 (ML176): a Synthetic RORα Selective Inverse Agonist. ACS Chem Biol. 2011 March 18; 6(3): 218-222.
[2]. Laura A. Solt, Thomas P. Burris. Action of RORs and their ligands in (patho)physiology. Trends in Endocrinology & Metabolism, 2012, 23(12): 619-627.
[3]. Kumar N, Nuhant P, Solt LA, et al. Identification of a novel selective inverse agonist probe and analogs for the Retinoic acid receptor-related Orphan Receptor Alpha (RORα). Probe Reports from the NIH Molecular Libraries Program [Internet], Bethesda (MD): National Center for Biotechnology Information (US),2010-.2010.